Juvenis Receives Exclusive Reluma Territories of Georgia, South Carolina, and Eastern Florida from Vestiage

Share Article

Vestaige, Inc announced today that it awarded the key exclusive territories of Georgia, South Carolina and Eastern Florida (Fort Lauderdale to Jacksonville) to Juvenis. Juvenis is based in Atlanta, Georgia and currently provides well known science-based injectables and skin care products to med spas, high rated salons, luxury resorts, select beauty retailers and physicians in the territories.


Juvenis is precisely the partner Vestiage was looking for in the Southern USA - Scott Kimball, CEO, Vestiage

Vestiage, Inc. (stock symbol "VEST") a publicly traded anti-aging company focused on science-based research and development, sales and marketing of premium branded highly effective anti-aging cosmeceuticals and nutraceuticals, announced today that it has awarded the key territories of Georgia, South Carolina, and Eastern Florida (Ft. Lauderdale to Jacksonville) to Juvenis Cosmetic Injectables based in Atlanta, Georgia. Juvenis currently covers the region offering well known science-based skin care injectables and skin care products to med spas, physicians, and is expanding its reach into high end salons, resorts, and speciality beauty retail boutiques with the Reluma product.

"Juvenis is precisely the kind of company that Vestiage was looking for to cover large territories and sell the Reluma product to our key customers," said Scott Kimball, CEO of Vestiage. "They have a built in customer base, they know skin care at the highest levels of science, they have an existing sales force, and they want to expand their business. Reluma is a great fit for them, and they are a really great fit for Vestiage."

Reluma is a human stem cell derived facial care brand in which the science, formulation, and ingredients surpass normal facial care products. Using the latest science and ingredients available and manufactured in the USA in laboratories located in California, Reluma acts to help stimulate the production of new skin at the cellular level, signaling human skin receptors with human growth factors created in thee laboratory.

Juvenis CEO Douglas Huber said, "We are very excited about representing the Reluma product line in the Southern USA. We have great relationships with our customers and Reluma can be a great way for us to expand our business and deepen the relationships we already have and bring in new customers."

Kimball, CEO of Vestiage, stated "We have all tried facial care and anti-aging lotions and potions over the years, and the reality is that the vast majority are mostly water, glycerin, mineral oil and other "filler" ingredients. This is why as consumers we have been consistently disappointed by this industry and why so many people have become numb to the stories the industry puts out. With Reluma, the most skeptical clientele become our biggest fans. Our clients know our product is very different almost immediately because they don't get that "watery" feeling from it. You get a feeling that this is a product packed with very rich, luxurious ingredients, elegantly formulated, using the latest science.

The Vestiage Territory Program awards exclusive Vestiage Metropolitan Statistical Areas ("MSA's") to qualified companies or individuals that sell to salons, spas, retailers, resorts and physicians in each MSA territory. Vestiage provides product literature, retail displays, product training, and marketing/sales support. The most lucrative MSA's in major cities are available to the most qualified organizations/individuals and will likely be in very high demand.

"The Reluma line is attractive to the higher rated salons and spas because it utilizes the latest science, the clientele love how it works for them, and financially the salon or spa can make a large amount of money simply by carrying the line and using it in stem cell facials," said Kimball. "The profit from the Reluma line alone can pay the overhead for the entire salon for a year by simply putting 2 women a day onto the Reluma Regimen."

The territories that remain available include: Dallas, Houston, Philadelphia, Chicago, Los Angeles (several), Orange County, California (2), San Francisco Bay Area (2), Seattle, San Diego, Colorado, Arizona, North Carolina, Washington DC/Northern Virginia, and more. For more information on the Vestiage Territory Program, please email your request to info(at)vestiageinc(dot)com or call 949-258-4404 and ask for Garrett Heiser, Vice President of Operations.

About Juvenis

Juvenis is a Georgia based distributor that markets cosmetics and injectables throughout the Southeastern United States. Juvenis has earned wide acceptance brokering products to licensed medical professionals at competitive prices. Our goal is to maintain a strong focus on customer service by making it a priority to meet the needs of our clients to ensure lasting relationships.

About Vestiage, Inc.

Vestiage (stock symbol "VEST") is a publicly traded anti-aging lifestyle company offering premium branded science-based cosmeceuticals and nutraceuticals. Vestiage is focused on the use of human stem cell, marine/ocean, and cutting edge botanically based science and ingredients to produce highly potent, elegantly formulated, effective products with clinically proven ingredients. Using high potency and novel ingredient combinations, Vestiage creates and distributes cosmeceuticals such as Reluma (http://www.RelumaSkinCare.com) and multifunctional nutraceuticals through Monterey Bay Nutraceuticals (http://www.MontereyBayNutra.com). Vestiage brands address the top “in demand” anti-aging consumer concerns. Vestiage research is focused on longevity and human performance science that covers both the cognitive and physical realms. As clinical results validate discoveries, Vestiage intends to apply new potential ingredients or ingredient formulations and combinations to its anti-aging products across brands. To learn more, visit the Company website, http://www.VestiageInc.com.

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forwardlooking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, anti-aging or stem cell facial care products or stem cell technology in general, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types, (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the anti-aging or cosmetics, beauty, or nutritional supplement industry or the healthy foods or anti-aging channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control. Copies of our reports are available upon request from our investor relations department or may be obtained at http://OTCMarkets.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Garrett Heiser
Follow us on
Visit website